期刊
NATURE REVIEWS CANCER
卷 14, 期 11, 页码 722-735出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3838
关键词
-
类别
资金
- National Health and Medical Research Council (NHMRC), Australia
- NHMRC [1003929]
For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarconna suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据